Adagene and City of Hope open small colorectal cancer study of two-drug combination
Adagene's muzastotug will be tested with ivonescimab in a study of up to 36 patients, but no financial or timing details were disclosed.
17 Nov 2026 · Adagene Inc. ADAG · Company news
Adagene and City of Hope said on 17 November 2026 that they have begun a small, academically led study of ivonescimab paired with Adagene's muzastotug (ADG126) in colorectal cancer. For Adagene, it extends the clinical footprint of muzastotug into a tumour type where the combination is now being tested in patients.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Adagene Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC
17 Nov 2026 · MAIA Biotechnology, Inc. MAIA · Company news